We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy.
- Authors
Zubiri, Leyre; Allen, Ian M.; Taylor, Martin S.; Guidon, Amanda C.; Chen, Steven T.; Schoenfeld, Sara R.; Neilan, Tomas G.; Sise, Meghan E.; Mooradian, Meghan J.; Rubin, Krista M.; Leaf, Rebecca Karp; Parikh, Aparna R.; Faje, Alexander; Gainor, Justin F.; Cohen, Justine V.; Fintelmann, Florian J.; Kohler, Minna J.; Dougan, Michael; Reynolds, Kerry L.
- Abstract
In 2018, a multi‐disciplinary workshop was held at the Massachusetts General Hospital to discuss challenges in defining, diagnosing, and treating immune‐related adverse events (irAE), including those that occur in patients administered PD‐1/L1 inhibitor combination therapy. In this commentary, the workshop participants present a clinical case that illustrates the complexity of irAE diagnosis and management in a patient receiving PD‐1/L1 combination therapy, summarize the current state of PD‐1/L1 combination therapy, and discuss challenges and opportunities for the evaluation of irAEs as these combinations become more widely used to treat patients with cancer.
- Subjects
ANTINEOPLASTIC agents; DIARRHEA; DRUG toxicity; IMMUNOTHERAPY; INTRAVENOUS therapy; MEMBRANE proteins; MONOCLONAL antibodies; ORAL drug administration; PREDNISONE; SIGMOIDOSCOPY; TUMORS; INFLIXIMAB; CARBOPLATIN; METHYLPREDNISOLONE; PEMETREXED; CHEMICAL inhibitors
- Publication
Oncologist, 2020, Vol 25, Issue 3, pe398
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.2018-0883